Bio-Rad Laboratories Q1 2024 Adj EPS $2.29 Beats $2.15 Estimate, Sales $610.820M Miss $619.092M Estimate
Portfolio Pulse from Benzinga Newsdesk
Bio-Rad Laboratories (NYSE:BIO) reported Q1 2024 adjusted EPS of $2.29, surpassing the $2.15 estimate, but saw a 31.44% decrease from the previous year's earnings. Sales reached $610.820M, falling short of the $619.092M estimate and marking a 9.75% decrease from the previous year.
May 07, 2024 | 8:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bio-Rad Laboratories reported a mixed Q1 2024 with EPS beating estimates but sales missing expectations and both earnings and sales seeing significant year-over-year declines.
The mixed earnings report with an EPS beat but a miss on sales and significant year-over-year declines could lead to uncertain short-term stock price movement. Investors might react positively to the earnings beat but could be concerned about the sales miss and the significant declines compared to the previous year.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100